Mar 05, 2020
Addyi Demonstrates Significant Improvements in Female Sexual Function for Arousal, Desire, Lubrication, Satisfaction, and Orgasm
Oct 16, 2019
Vyleesi(TM) Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress
Sep 09, 2019
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market to 2027: Affordable Reimbursement Scenario for Pharmacotherapy Employed in the Treatment of HSDD
Sep 04, 2019
FDA Removes Alcohol Ban with Addyi - the First-and-Only Non-Hormonal Treatment for Hypoactive (Low) Sexual Desire Disorder (HSDD)
Aug 29, 2019
BioPlus Specialty Pharmacy in Semi-Exclusive Relationship to Dispense Vyleesi(TM) (Bremelanotide Injection)
Jun 21, 2019
FDA Approves New Drug Application for Vyleesi(TM) (bremelanotide injection)
Jun 21, 2019
FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women
Apr 12, 2019
The Food and Drug Administration (FDA) Determines that Women Taking Addyi May Safely Consume Alcohol
Jan 04, 2019
S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys(TM) for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
Jun 27, 2018
Pivot Pharma To File Investigational New Drug (IND) Application With U.S. FDA For PVT-005
Jun 04, 2018
Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
Mar 26, 2018
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
Mar 12, 2018
Mayo Clinic Proceedings Publishes First Consensus Clinical Management of HSDD in Women Authored by ISSWSH
Nov 21, 2017
Palatin Technologies Announces Signing of Licensing Agreement with Kwangdong Pharmaceutical for Republic of Korea
Sep 06, 2017
Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories